Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients

被引:210
作者
Andrews, Peter J. D. [1 ,2 ]
Avenell, Alison [3 ]
Noble, David W. [4 ]
Campbell, Marion K. [3 ]
Croal, Bernard L. [5 ]
Simpson, William G. [5 ]
Vale, Luke D. [3 ,6 ]
Battison, Claire G. [1 ]
Jenkinson, David J. [3 ]
Cook, Jonathan A. [3 ]
机构
[1] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Lothian Univ, Western Gen Hosp, Hosp Div, Edinburgh EH4 2XU3, Midlothian, Scotland
[3] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland
[4] Aberdeen Royal Infirm, Dept Anaesthet & Intens Care, Aberdeen AB25 2ZN, Scotland
[5] Aberdeen Royal Infirm, Dept Clin Biochem, Aberdeen AB25 2ZN, Scotland
[6] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen AB25 2ZD, Scotland
来源
BMJ-BRITISH MEDICAL JOURNAL | 2011年 / 342卷
基金
英国医学研究理事会;
关键词
ENTERAL NUTRITION; FACTORIAL TRIALS; QUALITY;
D O I
10.1136/bmj.d1542
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine whether inclusion of glutamine, selenium, or both in a standard isonitrogenous, isocaloric preparation of parenteral nutrition influenced new infections and mortality among critically ill patients. Design Randomised, double blinded, factorial, controlled trial. Setting Level 2 and 3 (or combined) critical care units in Scotland. All 22 units were invited, and 10 participated. Participants 502 adults in intensive care units and high dependency units for >= 48 hours, with gastrointestinal failure and requiring parenteral nutrition. Interventions Parenteral glutamine (20.2 g/day) or selenium (500 mu g/day), or both, for up to seven days. Main outcome measures Primary outcomes were participants with new infections in the first 14 days and mortality. An intention to treat analysis and a prespecified analysis of patients who received >= 5 days of the trial intervention are presented. Secondary outcomes included critical care unit and acute hospital lengths of stay, days of antibiotic use, and modified SOFA (Sepsis-related Organ Failure Assessment) score. Results Selenium supplementation did not significantly affect patients developing a new infection (126/251 v 139/251, odds ratio 0.81 (95% CI 0.57 to 1.15)), except for those who had received >= 5 days of supplementation (odds ratio 0.53 (0.30 to 0.93)). There was no overall effect of glutamine on new infections (134/250 v 131/252, odds ratio 1.07 (0.75 to 1.53)), even if patients received >= 5 days of supplementation (odds ratio 0.99 (0.56 to 1.75)). Six month mortality was not significantly different for selenium (107/251 v 114/251, odds ratio 0.89 (0.62 to 1.29)) or glutamine (115/250 v 106/252, 1.18 (0.82 to 1.70)). Length of stay, days of antibiotic use, and modified SOFA score were not significantly affected by selenium or glutamine supplementation. Conclusions The primary (intention to treat) analysis showed no effect on new infections or on mortality when parenteral nutrition was supplemented with glutamine or selenium. Patients who received parenteral nutrition supplemented with selenium for >= 5 days did show a reduction in new infections. This finding requires confirmation.
引用
收藏
页数:8
相关论文
共 24 条
[1]   Thousands starving in UK hospitals [J].
Allan, Robert .
CLINICAL MEDICINE, 2007, 7 (05) :429-429
[2]  
Altman DG, 2000, STAT MED, V19, P3275, DOI 10.1002/1097-0258(20001215)19:23<3275::AID-SIM626>3.0.CO
[3]  
2-M
[4]   Randomised trial of glutamine and selenium supplemented parenteral nutrition for critically ill patients. Protocol version 9, 19 February 2007 known as SIGNET (Scottish Intensive Care Glutamine or seleNium Evaluative Trial) [J].
Andrews, Peter J. D. ;
Avenell, Alison ;
Noble, David W. ;
Campbell, Marion K. ;
Battison, Claire G. ;
Croal, Bernard L. ;
Simpson, William G. ;
Norrie, John ;
Vale, Luke D. ;
Cook, Jonathon ;
de Verteuil, Robyn ;
Milne, Anne C. .
TRIALS, 2007, 8 (1)
[5]  
ASPEN Board of Directors and the Clinical Guidelines Task Force, 2002, JPEN S1, V26, P1
[6]  
Avenell A, 2004, COCHRANE DB SYST REV, V4
[7]   Improving the quality of reporting of randomized controlled trials - The CONSORT statement [J].
Begg, C ;
Cho, M ;
Eastwood, S ;
Horton, R ;
Moher, D ;
Olkin, I ;
Pitkin, R ;
Rennie, D ;
Schulz, KF ;
Simel, D ;
Stroup, DF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (08) :637-639
[8]   A review of the true methodological quality of nutritional support trials conducted in the critically ill: Time for improvement [J].
Doig, GS ;
Simpson, F ;
Delaney, A .
ANESTHESIA AND ANALGESIA, 2005, 100 (02) :527-533
[9]  
Doig GS, 2010, INTENS CARE MED, V36, P1087
[10]   Selenium, systemic immune response syndrome, sepsis, and outcome in critically ill patients [J].
Forceville, X ;
Vitoux, D ;
Gauzit, R ;
Combes, A ;
Lahilaire, P ;
Chappuis, P .
CRITICAL CARE MEDICINE, 1998, 26 (09) :1536-1544